Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2014

View Archived Issues

U.S. researchers prepare new anti-B7-H5 antibodies

Biscayne Pharmaceuticals present data on novel GHRH antagonist

Ossianix extends research collaboration with Lundbeck for CNS therapeutics

Ascendis reports interim data from phase II pediatric study of TransCon Growth Hormone

Promising data presented on novel drug for the treatment of pyruvate kinase deficiency

Bone Therapeutics' phase I/IIa trial of Allob in delayed-union fractures recommended to continue

OncoSynergy forms agreement with CMC Biologics

MicroRNAs identified as potential markers of epilepsy

Antiangiogenic gene therapy evaluated in phase I/II glioblastoma study

Cardiac biomarkers have prognostic significance in coronary artery disease

Midafresa intravenous injection 0.1% for status epilepticus launched in Japan

Emergent BioSolutions acquires portfolio of broad-spectrum antibiotics

USAID awards funding to DNDi for onchocerciasis and elephantiasis

Tetraphase's eravacycline is noninferior to ertapenem in cIAI

Amunix confirms option exercise by Eli Lilly for XTEN product

Cara Therapeutics' CR-845 safe and well tolerated in patients undergoing hemodialysis

Cerulean initiates phase I/IIa trial of CRLX-301 docetaxel-bearing nanoparticles

Preclinical characterization of a novel dual orexin receptor antagonist

Bayer files BLA for BAY-81-8973 for treatment of hemophilia A

Janssen licenses recombinant hyaluronidase technology from Halozyme

Olaparib receives E.U. approval for BRCA-mutated ovarian cancer

Lilly divulges dopamine D1 receptor PAMs

Cellectis and bluebird bio report development of HIV treatment

Janssen Pharmaceutica prepares new mGlu2 receptor modulators

Abraxane approved for additional indication of unresectable pancreatic cancer in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...